Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.884,80 +256,32 (+0,68%) EUR/USD
1,0726 -0,0007 (-0,06%) Bitcoin EUR
59.937,85 +167,34 (+0,28%) CMC Crypto 200
1.388,94 +6,37 (+0,46%)
Allakos Inc. (ALLK)
Dopo ore:
| Chiusura precedente | 1,0200 |
| Aperto | 1,0100 |
| Denaro | 0,9684 x 100 |
| Lettera | 1,0200 x 400 |
| Min-Max giorno | 0,9799 - 1,0400 |
| Intervallo di 52 settimane | 0,9799 - 5,6400 |
| Volume | |
| Media Volume | 740.445 |
| Capitalizzazione | 89,43M |
| Beta (5 anni mensile) | 0,81 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,1400 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 2,90 |
GlobeNewswireAllakos Appoints Neil Graham to its Board of Directors
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan P
- GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events Presented preclinical data at the European Academy of Allergy and Clinical Immunology (“EAACI”) Hybrid Congress 2023 highlighting lirentelimab and AK006
- GlobeNewswire
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and curren
